Piramal Pharma Morpeth Solar Plant Installation
Analysis based on 16 articles · First reported Sep 16, 2026 · Last updated Sep 17, 2026
The announcement is a routine corporate sustainability initiative with negligible near-term impact on Piramal Group's earnings or valuation, though it modestly supports its long-term cost and ESG profile. Broader market impact is minimal, with only marginal positive read-through for the renewable energy and solar development sector.
Piramal Group Solutions (PPS), the contract development and manufacturing arm of Piramal Group, is installing a 4.3 MWp ground-mounted solar power plant at its integrated drug substance and drug product facility in Morpeth, United Kingdom. The plant will feature around 6,200 solar panels across 16 acres and is expected to supply approximately 3,950 MWh of renewable electricity annually, covering about 22% of the site's electricity demand. The project is being delivered under a Power Purchase Agreement with UL Solutions UK BTM1 Limited, a solar developer and independent power producer. Operations are scheduled to begin in the first quarter of 2027. The initiative supports Piramal Group's commitment to reduce Scope 1 and Scope 2 greenhouse gas emissions by 42% by FY2030 and is expected to avoid an estimated 20,000 tCO2e over 25 years. The announcement is a corporate sustainability and energy-resilience measure rather than a financially material transaction, with no disclosed capital expenditure figures.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard